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Interindividual variability in drug disposition is a major cause of lack of efficacy and adverse effects
of drug therapies. The majority of hepatically cleared drugs are metabolized by cytochrome P450
(CYP)  enzymes,  mainly  in  families  CYP1,  CYP2,  and  CYP3.  Genes  encoding  these  enzymes  are
highly variable with allele distribution showing considerable differences between populations.
Genetic variability of especially CYP2C9, CYP2C19, CYP2D6, and CYP3A5 is known to have clear
clinical impact on drugs that are metabolized by these enzymes. CYP1A2, CYP2A6, CYP2B6,
CYP2C8, and CYP3A4 all show variability that affects pharmacokinetics of drugs as well, but so far
the evidence regarding their clinical implications is not as conclusive. In this review, we provide an
up-to-date summary of the pharmacogenetics of the major human drug-metabolizing CYP enzymes,
focusing on clinically significant examples.
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1. Introduction
The cytochrome P450 (CYP) enzymes are a superfamily of hemoproteins, which have crucial
functions in the metabolism of both endogenous and xenobiotic compounds. In humans, 57 putatively
functional genes and 58 pseudogenes have been described (Nelson, Zeldin, Hoffman, Maltais, Wain,
& Nebert, 2004). Most of the genes, which are divided into 18 families and 44 subfamilies based on
their sequence similarity, have endogenous roles such as metabolism of bile acids, eicosanoids and
steroids (Nebert & Russell, 2002). Only about a dozen CYP enzymes belonging to families CYP1,
CYP2 and CYP3 are important for drug metabolism (Table 1). However, the majority of clinically
used drugs are metabolized by CYP enzymes (Zanger, Turpeinen, Klein, & Schwab, 2008), and many
drugs are predominantly metabolized by a single CYP enzyme at clinically relevant concentrations
in  humans.  Thus,  intrinsic  and  extrinsic  factors  that  influence  CYP  enzyme  activity  can  have
important effects on pharmacokinetics of drugs. For some drug-metabolizing CYP enzymes, in
particular CYP2C9, CYP2C19, and CYP2D6, genetic variability explains a large proportion of
variability in enzyme activity, whereas for some other CYPs, such as CYP1A2, and CYP3A4, this
proportion is much smaller (Zanger & Schwab, 2013). This review highlights the current knowledge
on the pharmacogenetics of drug-metabolizing CYP enzymes, as well as its clinical relevance.
2. Genetic variability of CYP enzymes
The drug-metabolizing CYP enzymes are genetically highly variable, in part due to low evolutionary
constraint  as many of them lack essential  endogenous function. The variability is  characterized by
common and rare single-nucleotide variants (SNVs), as well as copy-number variants (CNVs),
defined as duplications or deletions. The variants of CYP genes  are  defined  by  star  (*)  allele
nomenclature  for  which  the  Human  Cytochrome  P450  (CYP)  Allele  Nomenclature  Database  has
served as a central repository for over 15 years. The database has recently been transitioned to be
managed by the Pharmacogene Variation (PharmVar) Consortium available at www.PharmVar.org
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(Gaedigk, Ingelman-Sundberg, Miller, Leeder, Whirl-Carrillo, Klein et al., 2017). The functional
status of the variant alleles can range from no function to increased function, and thus phenotypes
ranging from poor metabolizer (PM) to ultrarapid metabolizer (UM) can be inferred from the
genotype (Table 2). In order to standardize the terminology used to describe allele functional status
and phenotype, a consensus paper was published by Clinical Pharmacogenetics Implementation
Consortium (CPIC) (Caudle, Dunnenberger, Freimuth, Peterson, Burlison, Whirl-Carrillo et al.,
2017). Lastly, to facilitate the transformation of pharmacogenetic knowledge into clinical practice
and to provide evidence-based guidelines on how available genetic test results should be used to
optimize drug therapy, several consortia have been established. Both CPIC and the Dutch
Pharmacogenetics Working Group (DPWG) provide genotype-based dosing guidelines based on
gene-drug pairs, with some differences in guideline development methods and the number of
guidelines produced so far (Bank, Caudle, Swen, Gammal, Whirl-Carrillo, Klein et al., 2017).
3. CYP1A subfamily
3.1 CYP1A2
CYP1A2 belongs to the CYP1 family and its gene is located on chromosome 15 along with CYP1A1
and CYP1B1. Their expression is regulated by the aryl hydrocarbon receptor (AhR) pathway.
CYP1A2 is abundantly expressed in the liver (Zhang, Wang, Gao, Wei, Tian, Zhao et al., 2016) and
it is involved in the metabolism of about 10% of clinically used drugs that are metabolized by CYP
enzymes (S. F. Zhou, Wang, Yang, & Liu, 2010). In contrast, CYP1A1 and CYP1B1 are mostly
extrahepatic, and are of lesser importance for drug metabolism. CYP1A2 is involved in the
metabolism of e.g., agomelatin, caffeine, clozapine, duloxetine, propranolol, tizanidine and
zolmitriptan,  as  well  as  some  endogenous  compounds,  such  as  melatonin  and  estradiol.  CYP1A2
activity is strongly affected by environmental factors. AhR mediated induction by smoking or food
6
components can markedly increase CYP1A2 activity. In contrast, oral contraceptives,
fluoroquinolones, and fluvoxamine inhibit CYP1A2 to a clinically relevant degree.
Several SNVs have been identified that affect CYP1A2 function, but they only partially
explain the variability in enzyme activity (Gunes & Dahl, 2008). The most common variants are
located in the 5´ flanking region, including CYP1A2*1F (defining variant rs762551, g.-163C>A)
which has a high frequency in many populations (Y. Zhou, Ingelman-Sundberg, & Lauschke, 2017).
On the other hand, nonsynonymous coding variants (CYP1A2*2 to *21) are rare. Caffeine is
frequently used to probe CYP1A2 activity, as caffeine N3-demethylation to paraxanthine is
selectively catalyzed by CYP1A2 (Fuhr, Rost, Engelhardt, Sachs, Liermann, Belloc et al., 1996).
CYP1A2 and AhR loci have been identified in several genomewide association studies to be linked
with  habitual  coffee  consumption  (Amin,  Byrne,  Johnson,  Chenevix-Trench,  Walter,  Nolte  et  al.,
2012; Coffee and Caffeine Genetics ConsortiumCornelisByrneEskoNallsGanna et al., 2015;
Cornelis, Monda, Yu, Paynter, Azzato, Bennett et al., 2011). CYP1A2*1F has been associated in
many studies with increased inducibility of CYP1A2 by e.g., smoking (Sachse, Brockmoller, Bauer,
& Roots, 1999), but otherwise its functional consequence is less clear. In any case, genetic effects on
CYP1A2 activity might be masked by environmental factors, in particular by smoking and oral
contraceptive use (Matthaei, Tzvetkov, Strube, Sehrt, Sachse-Seeboth, Hjelmborg et al., 2016), and
the conclusions thus can depend on the population studied. Furthermore, earlier studies including
only single variants might have missed more complex haplotypes including several variants. Taken
together, the current available evidence does not support CYP1A2 genotype-based dosing for any
drug.
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4. CYP2A and CYP2B subfamilies
4.1 CYP2A6
CYP2A6 represents about 4% of total hepatic microsomal CYP enzyme content, and it is also
expressed in some extrahepatic tissues, such as lungs and trachea (Di, Chow, Yang, & Zhou, 2009;
Ding & Kaminsky, 2003; Zhang et al., 2016). In comparison to other CYP enzymes, CYP2A6 has a
small active site (Yano, Hsu, Griffin, Stout, & Johnson, 2005). It has a major role in the metabolism
of coumarin, letrozole, nicotine, and tegafur, and it contributes to the metabolism of other drugs, such
as artemisin, efavirenz, halothane, pilocarpine, and valproic acid.
CYP2A6 gene is highly variable, with over 40 star alleles described to date, along with
additional suballeles (https://www.pharmvar.org/gene/CYP2A6, accessed 5 February 2018). The
spectrum of CYP2A6 variant alleles include SNVs (e.g., CYP2A6*2, *6), gene deletions (e.g., *4A-
H), a hybrid gene with CYP2A7 (e.g., *3, *12A-C), and gene conversions (e.g., *1B1-17)
(McDonagh, Wassenaar, David, Tyndale, Altman, Whirl-Carrillo et al., 2012). In principle, CYP2A6
phenotype, ranging from poor to ultrarapid metabolizer, can be inferred from CYP2A6 genotype.
However,  the  effects  of  CYP2A6  variant  alleles  are  known  to  be  substrate  specific  (Fukami,
Nakajima, Higashi, Yamanaka, Sakai, McLeod et al., 2005), and due to the high number of different
variants and complex genetic architecture, variant allele carriers may be misclassified as e.g., wild-
type due to limitations in genotyping methods used (Hoffman, Nelson, & Keeney, 2001). In addition,
the distribution of variant alleles varies greatly between populations (Y. Zhou et al., 2017). The
decreased function allele CYP2A6*9 is common in all major populations (minor allele frequency
(MAF)  ranging  from  8%  in  Africans  to  23%  in  East  Asians),  whereas CYP2A6*17, CYP2A6*23,
CYP2A6*25, and CYP2A6*28 are only found in Africans, and CYP2A6*7, and CYP2A6*19 in East
Asians. In Europeans, the most common variant alleles leading to decreased function are CYP2A6*9,
and CYP2A6*35 with MAFs of 11% and 15%, respectively.
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The metabolism of nicotine to cotinine is strongly related to CYP2A6 activity, and
CYP2A6 variants largely explain inter-individual variability in the metabolism of nicotine to cotinine
(Bloom, Hinrichs, Wang, von Weymarn, Kharasch, Bierut et al., 2011; Hukkanen, Jacob, &
Benowitz, 2005). CYP2A6 variant alleles associated with reduced nicotine metabolism have been
linked with lesser likelihood of becoming smoker, lower cigarette consumption, and better ability to
quit than normal metabolizers in many studies (McDonagh et al., 2012; Ray, Tyndale, & Lerman,
2009).
CYP2A6 is involved in the bioactivation of tegafur to 5-fluorouracil, and genetic variation of
CYP2A6 has been associated with altered tegafur metabolism, and also clinical outcomes in some
studies (Kaida, Inui, Suda, Nakamura, Watanabe, & Chida, 2008; Kong, Lim, Nam, Kook, Kim, Ryu
et al., 2009; Park, Kong, Nam, Choi, Kim, Lee et al., 2011). These results suggest that bioactivation
of tegafur is impaired in CYP2A6 poor metabolizers, but the associations with clinical endpoints have
not been replicated in all studies, and they may be dependent on the cancer type and combination
treatment given (Tanner & Tyndale, 2017). In addition, decreased function alleles of CYP2A6 have
been associated with increased plasma concentrations of another anticancer agent, letrozole (Desta,
Kreutz, Nguyen, Li, Skaar, Kamdem et al., 2011; Tanii, Shitara, & Horie, 2011). It remains to be
determined, however, whether the genotype has an impact on the efficacy and side effects of letrozole.
In addition, CYP2A6 variants have been reported to have an influence on the pharmacokinetics of
efavirenz and valproic acid, even though other enzymes contribute the elimination of these drugs
(Tanner & Tyndale, 2017).
4.2 CYP2B6
Similarly to CYP2A6, the expression of CYP2B6 is highly variable, and it represents only a small
percentage of the total hepatic microsomal CYP content (H. Wang & Tompkins, 2008; Zhang et al.,
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2016). CYP2B6 and CYP2A6 are located in close proximity in chromosome 19, and their expression
levels are correlated (Al Koudsi & Tyndale, 2010). In addition to the liver, CYP2B6 is also expressed
in the brain (Miksys & Tyndale, 2004). It is involved in the metabolism of e.g., bupropion,
cyclophosphamide, efavirenz, methadone, and nevirapine (Turpeinen & Zanger, 2012; H. Wang &
Tompkins, 2008).
Currently, 38 CYP2B6 variants with designated star alleles are described
(https://www.pharmvar.org/gene/CYP2B6, accessed 5 February 2018). The most widely studied
allele is CYP2B6*6, (c.516G>T, c.785A>G) resulting in reduced expression, which is found with a
MAF  of  3%  in  Europeans,  6%  in  Africans,  3%  in  East  Asians,  16%  in  South  Asians,  and  3%  in
admixed Americans (Y. Zhou et al., 2017). The most common variant allele in all major populations
is CYP2B6*9 (c.516G>T), but its functional significance is less clear. Alleles with increased function
have also been described (CYP2B6*4 and CYP2B6*22),  with  a  MAF  of  <2%  in  most  major
populations, with the exception of CYP2B6*22 with a MAF of about 4% in Africans.
The nonnucleoside reverse transcriptase inhibitor efavirenz is metabolized
predominantly by CYP2B6. Several studies have shown an association between CYP2B6 genotype,
in particular the reduced function CYP2B6*6 allele, and efavirenz related adverse effects including
central nervous system toxicity and hepatotoxicity (Vo & Varghese Gupta, 2016). On the other hand,
the effect on clinical outcomes has not been as widely replicated. Genotype-based dose reduction of
efavirenz in CYP2B6 poor metabolizers has been performed in some studies (Gatanaga, Hayashida,
Tsuchiya, Yoshino, Kuwahara, Tsukada et al., 2007). Interestingly, even though CYP2A6 is a minor
metabolic pathway for efavirenz in general, CYP2A6*9 has been associated with increased efavirenz
plasma concentrations in CYP2B6 poor metabolizers (Haas, Kwara, Richardson, Baker,
Papageorgiou, Acosta et al., 2014). To date, no genotype-based dosing guideline has been published,
but efavirenz is a potential candidate for such a guideline with emerging evidence.
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CYP2B6*6 has been associated with reduced metabolism of bupropion, a pro-drug
which  is  activated  by  CYP2B6.  The  effect  of CYP2B6*6 allele on the efficacy of bupropion on
smoking cessation has been shown in some, but not all, studies (Chenoweth & Tyndale, 2017; Lee,
Jepson, Hoffmann, Epstein, Hawk, Lerman et al., 2007; Zhu, Cox, Nollen, Faseru, Okuyemi,
Ahluwalia et al., 2012)). Pharmacokinetics of several other CYP2B6 substrates, such as
cyclophosphamide, methadone and nevirapine have been reported to be influenced by CYP2B6
genotype, but evidence regarding them is not yet conclusive (Zanger & Klein, 2013).
5. CYP2C subfamily
The CYP2C subfamily consists of four highly homologous genes CYP2C18-CYP2C19-CYP2C9-
CYP2C8, which are located in this order from centromere to telomere on chromosome 10q23.33.
Even though CYP2C18 mRNA is highly expressed in the liver, it does not get efficiently translated
into  protein  (Läpple,  von  Richter,  Fromm,  Richter,  Thon,  Wisser  et  al.,  2003).  The  other  CYP2C
enzymes are expressed in the liver in the order CYP2C9 > CYP2C8 > CYP2C19, and, to a lesser
extent, in the small intestine (Zhang et al., 2016). CYP2C enzyme activities can be markedly altered
by environmental factors. A variety of xenobiotics such as rifampicin, and hyperforin can induce the
transcriptional expression of CYP2C genes in hepatocytes and thereby increase the metabolism of
CYP2C substrates. Several drug-activated nuclear receptors including CAR, PXR, VDR, and GR
have been implicated in this induction (Chen & Goldstein, 2009). Many drugs can also act as
reversible or time-dependent inhibitors of CYP2C enzymes, such as clopidogrel and gemfibrozil for
CYP2C8, fluconazole and miconazole for CYP2C9, and fluvoxamine and omeprazole for CYP2C19.
5.1 CYP2C8
CYP2C8 has been established as one of the key drug-metabolizing CYP enzymes during the last 15
years (Backman, Filppula, Niemi, & Neuvonen, 2016). CYP2C8 metabolizes a variety of xenobiotics
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and drugs, including amodiaquine, dasabuvir, imatinib, paclitaxel, loperamide, montelukast,
pioglitazone, repaglinide, and rosiglitazone, for example.
There are tens of SNVs, short deletions and essential splice site variants that have been
found in the CYP2C8 gene. Fourteen CYP2C8 alleles have a designated star allele
(https://www.pharmvar.org/gene/CYP2C8, accessed 31 Jan 2018). The alleles CYP2C8*2, *3 and *4
account for the majority of nonsynonymous variability of CYP2C8 in humans (Y. Zhou et al., 2017).
CYP2C8*2 (c.805A>T, p.Ile269Phe; rs11572103) occurs with an allele frequency ranging from about
10% to 37% in individuals with a sub-Saharan African ancestry. However, this allele is rare or absent
in most Asian, European and admixed American populations. The CYP2C8*3 allele consists of two
nonsynonymous variants (c.416G>A, p.Arg139Lys; rs11572080, and c.1196A>G, p.Lys399Arg;
rs10509681) that are in complete or nearly complete linkage. CYP2C8*3 is also in linkage
disequilibrium with the CYP2C9*2 allele (Yasar, Lundgren, Eliasson, Bennet, Wiman, de Faire et al.,
2002). In individuals with a European ancestry, the allele frequency of CYP2C8*3 approximates 11%
(Y. Zhou et al., 2017). In South Asian and admixed American populations the frequency of the allele
is about 4% and 7%, respectively, while in Sub-Saharan African populations the frequency is
generally very low, albeit highly variable. Like CYP2C8*3, the CYP2C8*4 allele (c.792C.G,
p.Ile264Met; rs1058930) is more common in European than in other populations. In most
populations, its frequency is lower (by a factor of about two) than that of CYP2C8*3.
The clinical significance of CYP2C8 pharmacogenetics seems to be limited (Backman
et al., 2016). Most in vitro studies have suggested that the CYP2C8*2, *3 and *4 alleles result in
moderately decreased CYP2C8 function. However, also opposite findings have been reported
regarding the *3 and *4 alleles, for example with respect to the metabolism of cerivastatin (Kaspera,
Naraharisetti, Tamraz, Sahele, Cheesman, Kwok et al., 2010). Many clinical studies have suggested
an increased CYP2C8 activity for carriers of the *3 allele. Individuals with the CYP2C8*1/*3
genotype have had an approximately 40-50% lower repaglinide AUC than individuals with the
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CYP2C8*1/*1 genotype (Backman et al., 2016). In addition, the AUCs of rosiglitazone or
pioglitazone  have  been  about  20-40%  lower  in CYP2C8*3 carriers than in noncarriers, with an
apparent gene-dose effect. In accordance with the pharmacokinetic findings, CYP2C8*3 has been
associated with reduced glycemic response to rosiglitazone treatment in two studies in patients with
type 2 diabetes mellitus (Dawed, Donnelly, Tavendale, Carr, Leese, Palmer et al., 2016; Stage,
Christensen, Feddersen, Beck-Nielsen, & Brøsen, 2013). Furthermore, in a recent study, CYP2C8*3
carriers (n = 34) had a slightly higher imatinib metabolic ratio than did CYP2C8*1/*1 (n = 147)
patients (Barratt, Cox, Menelaou, Yeung, White, Hughes et al., 2017).
In contrast to the clinical findings with repaglinide and thiazolidinediones, the CYP2C8*3
allele has been associated with a slightly impaired clearance of paclitaxel (Bergmann, Brasch-
Andersen, Green, Mirza, Pedersen, Nielsen et al., 2011; Henningsson, Marsh, Loos, Karlsson, Garsa,
Mross et al., 2005) and an increased risk for paclitaxel-induced neurotoxicity or myelosuppression
(Backman et al., 2016; Boora, Kanwar, Kulkarni, Abyzov, Sloan, Ruddy et al., 2016; Lam, Frederiks,
van  der  Straaten,  Honkoop,  Guchelaar,  &  Boven,  2016).  Thus,  it  seems  that  the  influence  of
CYP2C8*3 on drug metabolism may be substrate dependent and is usually only modest. Based on
limited evidence, CYP2C8*2 and *4 alleles  appear  to  have  some,  but  limited,  effect  on  the
pharmacokinetics of CYP2C8 substrates. Inactive CYP2C8 alleles, such as *5, *7 and *11 are rare
(Y. Zhou et al., 2017), but as case reports have shown, such alleles can drastically increase the risk
of adverse reactions (Backman et al., 2016). At present, there are no genotype-based consensus
guidelines for CYP2C8.
5.2 CYP2C9
CYP2C9 is one of the most important CYP enzymes in terms of the number of substrates; it has
been estimated to contribute to the metabolism of approximately 15% of all drugs that are
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metabolized by CYP enzymes (Daly, Rettie, Fowler, & Miners, 2017; Kirchheiner & Brockmöller,
2005). Important CYP2C9 substrates include warfarin (S-isomer), acenocoumarol, phenytoin,
losartan, fluvastatin, bosentan, most sulphonylureas and several nonsteroidal anti-inflammatory
agents.
Two nonsynonymous polymorphisms, rs1799853 (c.430C>T, p.Arg144Cys) and
rs1057910 (c.1075A>C, p.Ile359Leu), define the CYP2C9*2 and CYP2C9*3 alleles, respectively
(https://www.pharmvar.org/gene/CYP2C9, accessed 31 Jan 2018). They are the best studied alleles
largely because they are functionally detrimental and globally the most common CYP2C9 variants.
Altogether, there are 60 CYP2C9 variants with a star allele name and tens of other single nucleotide
variants (SNVs) in the regulatory and coding regions of the CYP2C9 gene. Apart from CYP2C9*2
and CYP2C9*3, some of the alleles are also relatively common and at least CYP2C9*5, CYP2C9*6,
CYP2C9*11, CYP2C9*12 and CYP2C9*13 can produce an enzyme with markedly reduced activity
(Daly et al., 2017).
The allele frequencies of CYP2C9*2 and CYP2C9*3 are around 12% and 6% in European
subjects (Y. Zhou et al., 2017). CYP2C9*2 is also relatively common in admixed Americans (7%),
South Asians (5%) and Africans (2%) but very rare in East Asians, while CYP2C9*3 is remarkably
common in South Asians (11%) and fairly common in East Asians and Americans (3-4%). CYP2C9*3
is generally associated with a more than 80% reduction in CYP2C9 mediated intrinsic clearance,
while the effect of CYP2C9*2 is generally slightly smaller and varies considerably, depending on the
substrate (Daly et al., 2017). Interestingly, CYP2C9*8 and CYP2C9*9 are more common (6% and
8%) than the *2 and *3 alleles in Africans, but extremely rare in Europeans (Y. Zhou et al., 2017). In
addition, also CYP2C9*5, CYP2C9*6 and CYP2C9*11 are much more common among Africans than
among Europeans and CYP2C9*14 is fairly common in South Asians, while all other alleles are rare
in major populations. Based on genotypes, individuals can be classified as normal (*1/*1),
intermediate (IM, carrier of one decreased-function allele) or poor (carrier of two decreased-function
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alleles) metabolizers (Table  2).  About  30%  of  Europeans  are  IMs  and  4%  are  PMs,  and  the
frequencies of these phenotypes are somewhat lower in other populations (Table 3).
One of the most sensitive drugs to genetic variability in CYP2C9 activity is warfarin,
since its S-isomer is metabolized almost exclusively by CYP2C9 (Baker & Johnson, 2016; Rettie,
Korzekwa, Kunze, Lawrence, Eddy, Aoyama et al., 1992). Consequently, the oral clearance of S-
warfarin is reduced by 70-85% in CYP2C9 PMs and about 40% in IMs, leading to a longer S-warfarin
half-life, longer delay in reaching a stable INR, lower warfarin dose requirement, and increased risk
of bleeding during warfarin treatment, particularly in PMs (Jorgensen, FitzGerald, Oyee,
Pirmohamed, & Williamson, 2012). Apart from CYP2C9 variants (explain about 6% to 19% of
variability in dose requirement), a number of other factors contribute to warfarin dose requirement,
including vitamin K epoxide reductase complex subunit 1 (VKORC1) and CYP4F2 genotypes, patient
age, body size, smoking status and certain concomitant medications. Various algorithms have been
developed to guide warfarin dosing on the basis of these factors. The first algorithm developed on a
sufficient patient population was published 10 years ago by Gage et al. (Gage, Eby, Johnson, Deych,
Rieder, Ridker et al., 2008) and is currently in use as a modified and updated web-based calculator
(www.warfarindosing.org). A large worldwide project, International Warfarin Pharmacogenetics
Consortium (IWPC), also developed a definitive warfarin dosing algorithm using clinical and genetic
data on about 5000 patients treated with warfarin, including different ethnicities (International
Warfarin Pharmacogenetics Consortium, Klein, Altman, Eriksson, Gage, Kimmel et al., 2009).
Three large randomized controlled trials, termed CoumaGen-II, EU-PACT and GIFT,
comparing the above warfarin dosing algorithms to various conventional non-genetic approaches
suggested that genotype-based dosing can be beneficial when warfarin treatment is initiated
(Anderson, Horne, Stevens, Woller, Samuelson, Mansfield et al., 2012; Gage, Bass, Lin, Woller,
Stevens, Al-Hammadi et al., 2017; Pirmohamed, Burnside, Eriksson, Jorgensen, Toh, Nicholson et
al., 2013). However, in the fourth randomized study, COAG, the time within therapeutic range in the
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first 4 weeks of warfarin treatment was not improved by genotype-based dosing, and the outcome
was even worse in the genotyped African-Americans than in the controls (Kimmel, French, Kasner,
Johnson, Anderson, Gage et al., 2013). The poor result of the COAG study may be partly explained
by that CYP2C9 genotyping included only the *2 and *3 alleles, but not the common African alleles.
Accordingly, more comprehensive algorithms have been developed, and the warfarindosing.org
website now contains both the Gage algorithm and the IWPC algorithm and enables adjustments for
CYP4F2, CYP2C9*5 and *6. The CPIC guideline for pharmacogenetics-guided warfarin dosing and
its annotations (https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/)
provide detailed instructions on how to use pharmacogenetic algorithms for warfarin dosing (Johnson,
Caudle, Gong, Whirl-Carrillo, Stein, Scott et al., 2017). Apart from warfarin, CYP2C9 genotype
influences to some degree also the pharmacokinetics of the other coumarins acenocoumarol and
phenprocoumon.
In addition to anticoagulants, CYP2C9 *2 and *3 alleles can markedly reduce the
clearances of sulfonylureas, particularly tolbutamide and glipizide (Kirchheiner & Brockmöller,
2005). Clinical studies and case reports have suggested that CYP2C9 variant allele carriers are more
sensitive to the hypoglycaemic effect of sulfonylureas and may be at risk of hypoglycaemia (Daly et
al., 2017). In addition, CYP2C9 variant alleles markedly affect the pharmacokinetics of a number of
nonsteroidal anti-inflammatory drugs, including celecoxib, ibuprofen and flurbiprofen. There are also
several studies suggesting that CYP2C9 variant carriers are at an increased risk of NSAID-associated
gastrointestinal bleeding (Figueiras, Estany-Gestal, Aguirre, Ruiz, Vidal, Carvajal et al., 2016).
The antiepileptic drug phenytoin has a narrow therapeutic index and complex
pharmacokinetic characteristics, including saturable metabolism and dependence on CYP2C9 activity
(Caudle, Rettie, Whirl-Carrillo, Smith, Mintzer, Lee et al., 2014). Both CYP2C9*2 and CYP2C9*3
are associated with impaired clearance of phenytoin. Consequently, it has been reported that
phenytoin maintenance doses are reduced by about 30% in heterozygous carriers of these CYP2C9
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alleles and by 30-50% in homozygous carriers, compared to noncarriers. Furthermore, case reports
suggest that CYP2C9 PMs are at increased risk for dose-related phenytoin toxicities. Accordingly,
the respective CPIC guideline recommends a 25-50% reduction of phenytoin starting maintenance
dose in decreased function CYP2C9 allele carriers, with subsequent maintenance doses adjusted based
on therapeutic drug monitoring or response (Caudle et al., 2014).
5.3 CYP2C19
CYP2C19 participates in the metabolism of many clinically relevant drugs such as benzodiazepines,
proton pump inhibitors (PPIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic
antidepressants (TCAs) and voriconazole, and it is important for the metabolic activation of the
prodrug clopidogrel.
CYP2C19 is highly variable with 35 defined haplotypes with a designated star allele so
far  (https://www.pharmvar.org/gene/CYP2C19, accessed 14 Jan 2018). The most common no
function allele is CYP2C19*2 (c.681G>A; rs4244285), occurring with an allele frequency of 18% in
Africans and Europeans, and over 30% in Asian populations (Y. Zhou et al., 2017). Other decreased
or  no  function  alleles  (*3-*8)  are  typically  rare,  with  the  exception  of CYP2C19*3 (c.636G>A;
rs4986893) in East Asians with a MAF of about 7%. On the other hand, the increased function
CYP2C19*17 allele (c.-806C>T; rs12248560) results in enhanced transcription probably due to the
modulation of GATA4 binding (Mwinyi, Hofmann, Pedersen, Nekvindova, Cavaco, Mkrtchian et al.,
2010). It is common in Europeans and Africans (MAF about 23%), less common in admixed
Americans and South Asians (12-14%), and almost absent in East Asians. Thus, CYP2C19 phenotype
ranges from PM to UM (Table 3).
The clinical significance of CYP2C19 pharmacogenetics is well established. For
example, clopidogrel is a prodrug, which is activated in two sequential oxidative steps involving
several CYP enzymes, including CYP2C19 (Kazui, Nishiya, Ishizuka, Hagihara, Farid, Okazaki et
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al., 2010). Many studies have indicated that the bioactivation of clopidogrel is impaired in CYP2C19
poor metabolizers and that these PMs have lower levels of clopidogrel active metabolite than normal
metabolizers (Scott, Sangkuhl, Stein, Hulot, Mega, Roden et al., 2013). Moreover, there is substantial
evidence linking CYP2C19 genotype  with  clinical  outcomes,  especially  in  patients  with  acute
coronary syndrome who have undergone percutaneous coronary intervention (Mao, Jian, Changzhi,
Dan, Suihua, Wenyi et al., 2013; Mega, Simon, Collet, Anderson, Antman, Bliden et al., 2010). More
recently, a meta-analysis of clopidogrel-treated patients with stroke or transient ischemic attack
suggested a similar level of risk for vascular events than that reported for patients with coronary artery
disease (Y. Pan, Chen, Xu, Yi, Han, Yang et al., 2017), and the risk seems to be attenuated in stroke
patients treated with clopidogrel monotherapy (Sun, Li, Li, Zhang, Zhu, Liu et al., 2015; Tornio,
Flynn, Morant, Velten, Palmer, MacDonald et al., 2018). On the other hand, the increased function
CYP2C19*17 allele has been associated with increased risk of bleeding in some studies (Sibbing,
Koch, Gebhard, Schuster, Braun, Stegherr et al., 2010). Based on the current available evidence,
alternative antiplatelet therapy is recommended for CYP2C19 IMs and PMs in the CPIC guideline
(Scott et al., 2013).
There  is  also  strong  evidence  on  the  influence  of CYP2C19 genotype on TCAs and
SSRIs that are metabolized by CYP2C19 (Hicks, Sangkuhl, Swen, Ellingrod, Muller, Shimoda et al.,
2016). Tertiary amine TCAs, namely amitriptyline, clomipramine, doxepin, imipramine, and
trimipramine, are demethylated by CYPC19 to corresponding pharmacologically active secondary
amines (e.g., amitriptyline to nortriptyline), and both the tertiary amines and secondary amines are
metabolized by CYP2D6 to less active hydroxy-metabolites. Tertiary amines have a stronger
serotonergic effect, whereas secondary amines have a more pronounced noradrenergic effect, and
thus  changes  in  CYP2C19  activity  can  have  an  impact  on  clinical  response  or  adverse  effects  of
tertiary amines (Gillman, 2007). Both CYP2C19 poor and ultrarapid/rapid metabolizers are at risk of
suboptimal response to tertiary amines, and other TCAs not metabolized by CYP2C19 are
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recommended for these individuals in the CPIC guideline (Hicks et al., 2016). Furthermore, the SSRIs
citalopram, escitalopram, and sertraline are metabolized by CYP2C19, and especially for citalopram
and escitalopram, CYP2C19 UMs are at risk of therapeutic failure and PMs at increased risk of side
effects if normal recommended doses are used (Hicks, Bishop, Sangkuhl, Müller, Ji, Leckband et al.,
2015; Jukic, Haslemo, Molden, & Ingelman-Sundberg, 2018).
Most PPIs are metabolized by CYP2C19 and their pharmacokinetics are affected by
CYP2C19 phenotype (Furuta, Ohashi, Kamata, Takashima, Kosuge, Kawasaki et al., 1998). Both
CYP2C19 IMs and PMs have higher PPI plasma concentrations compared to NMs, and consequently,
the success rate of H. Pylori eradication therapy depends on CYP2C19 genotype (Zhao, Wang, Yang,
Wang,  Shi,  Xu  et  al.,  2008).  In  contrast,  CYP2C19  UMs  are  at  risk  of  treatment  failure,  and
consequently dose escalation is recommended for esomeprazole, lansoprazole, omeprazole and
pantoprazole in H. Pylori eradication in the UM patients according to the DPWG guideline (Swen,
Nijenhuis, de Boer, Grandia, Maitland-van der Zee, Mulder et al., 2011). Also the triazole antifungal
voriconazole is metabolized by CYP2C19, and choosing an alternative antifungal agent not
metabolized by CYP2C19 is recommended for both rapid/ultrarapid metabolizers and poor
metabolizers due to risk of subtherapeutic concentrations and risk of adverse effects, respectively
(Moriyama, Obeng, Barbarino, Penzak, Henning, Scott et al., 2016).
6. CYP2D6
Although the protein abundancy of CYP2D6 in the liver is only about 5% of the total hepatic CYP
amount (Y. Zhou et al., 2017), CYP2D6 contributes significantly to the metabolism of roughly 25%
of all drugs in clinical use (He, Chen, Zhou, & Zhou, 2015). CYP2D6 substrates include TCAs, SSRIs
(paroxetine, fluoxetine, fluvoxamine), other psychiatric drugs (venlafaxine, aripiprazole,
risperidone), atomoxetine, opioids (codeine, tramadol, oxycodone), antiemetics (ondansetron,
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tropisetron), primaquine, tamoxifen, and cardiovascular drugs (metoprolol, timolol, propafenone).
CYP2D6 is inhibited strongly by various drugs, including fluoxetine, paroxetine, terbinafine and
moclobemide. Moreover, although it has been thought that CYP2D6 is not inducible, accumulating
data indicate that transcriptional regulation of CYP2D6 may account for part of CYP2D6 variability
(X. Pan, Ning, & Jeong, 2017).
The CYP2D6 gene is located on Chr22q13.1 in close proximity to the nonfunctional
pseudogenes, CYP2D7 and CYP2D8. There are more than 100 variants with a designated star allele
in the highly polymorphic CYP2D6 locus, including CNVs
(https://www.pharmvar.org/gene/CYP2D6, accessed 31 Jan 2018). Overall, the different variations
confer no, decreased, normal, or increased function, leading to huge variability in enzyme activity
between individuals and populations, ranging from PMs (individuals with two nonfunctional alleles)
to UMs (usually carriers of more than two functional CYP2D6 alleles due to gene duplication) (Table
3). The CYP2D6 diplotypes can be translated into predicted more definitive phenotypes using the
activity score (AS) system (Gaedigk, Sangkuhl, Whirl-Carrillo, Klein, & Leeder, 2017; Gaedigk,
Simon, Pearce, Bradford, Kennedy, & Leeder, 2008). To calculate the activity score, alleles are
grouped according to their functionality, and a value is assigned to each allele to calculate the AS of
each diplotype: no-function (0) alleles (*3, *4, *4xN,*5, *6, *7, *8, *11, *12, *36, *40, *42, *56),
decreased-function (0.5) alleles (*9, *10, *17, *29, *41, *44, *49), normal-function (1) alleles (*2,
*35, *43, *45), and increased-function (2) alleles (*1xN, *2xN). Accordingly, the CYP2D6 phenotype
can thus be inferred as poor (AS 0), intermediate (0.5), normal (1-2) or ultrarapid (> 2) metabolizer.
There is lack of consensus concerning whether patients with an AS of 1.0 should be assigned a normal
or intermediate phenotype, and in some reports, they have been classified as normal-slow
metabolizers, and individuals with an AS of 1.5-2 as normal-fast metabolizers (Gaedigk, Sangkuhl,
et al., 2017; Gaedigk et al., 2008).
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CYP2D6 allele frequencies vary substantially between populations. The CYP2D6*2 allele,
conferring normal CYP2D6 function, and the variant defining CYP2D6*4 (rs3892097), causing a
splicing defect and an inactive CYP2D6 gene product, are frequent in European, African, South
Asian, and admixed American populations, with allele frequencies of 27-36% and 12-16%,
respectively (Y. Zhou et al., 2017). On the other hand, the inactive alleles CYP2D6*3 (4%)  and
CYP2D6*6 (2%) are only found in individuals of European ancestry, while the decreased function
allele CYP2D6*10 is almost exclusively found in African, South Asian, and particularly in East Asian
populations, where it is the most common CYP2D6 allele (59%). CYP2D6*14 is only found in East
Asian populations (2%), while CYP2D6*17 (20%), CYP2D6*29 (9%),  and CYP2D6*43 (2%) are
African haplotypes. The duplicated increased-function alleles CYP2D6*1xN and CYP2D6*2xN occur
with frequencies of 1–2% in whites and Asians but are much more common in certain African
populations, in which their frequency can be up to 29%, and can be enriched in some smaller
populations, such as the Finns (7%) (Pietarinen, Tornio, & Niemi, 2016). The frequencies of deletions
(CYP2D6*5) vary from 1% to 7% (Gaedigk, Sangkuhl, et al., 2017).
 Codeine is a weak opioid analgesic, whose opioid effect is dependent on morphine
formed by CYP2D6 (Crews, Gaedigk, Dunnenberger, Leeder, Klein, Caudle et al., 2014).
Accordingly, the rate of bioactivation and analgesic efficacy of codeine are markedly decreased in
CYP2D6 PMs and increased in UMs, even though clinical evidence from pain studies regarding the
effect of CYP2D6 genotype is still lacking (Somogyi, Coller, & Barratt, 2015). There are several case
reports of severe or life-threatening adverse effects following standard codeine doses in CYP2D6
UMs. Consequently, the CPIC guideline recommends using alternative analgesics in PMs and UMs,
and codeine is contraindicated by the medicines agencies in known CYP2D6 UMs. In addition to
codeine, also other opioids, including tramadol, hydrocodone and oxycodone, are O-demethylated by
CYP2D6. As O-desmethyltramadol is mainly responsible for the opioid effects of tramadol, similarly
to codein, CYP2D6 PMs and UMs can be  susceptible to treatment failure when tramadol is used
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(Orliaguet, Hamza, Couloigner, Denoyelle, Loriot, Broly et al., 2015). However, the effect of genetic
variability in CYP2D6 on the analgesic efficacy and risk of toxicity with oxycodone and
hydromorphone seems to be smaller due to the variable significance of parent drug and metabolites
to the opioid effects.
All TCAs are metabolized to less active hydroxylated metabolites almost exclusively by
CYP2D6 (Hicks et al., 2016). Therefore, there is huge CYP2D6 genotype dependent variability in
their metabolic clearance. Accordingly, clinical studies have shown particularly for amitriptyline and
nortriptyline that standard doses of TCAs can fail to produce sufficient drug concentrations in the
systemic circulation in UMs, while the concentrations of TCAs may reach supratherapeutic levels in
PMs, resulting in risk of therapeutic failure or intolerable adverse effects, respectively. The CPIC
guideline therefore recommends avoiding TCAs in CYP2D6 UMs and PMs.
Of the SSRIs, fluoxetine, and particularly fluvoxamine and paroxetine are metabolized by
CYP2D6 (Hicks et al., 2015). CYP2D6 UMs have been shown to be at risk of low or undetectable
plasma paroxetine concentrations, which may be associated with an increased likelihood of
therapeutic failure. Therefore, it is advisable to select an alternative antidepressant in UMs. CYP2D6
PMs, on the other hand have greater drug exposure to fluvoxamine and paroxetine, compared to NMs,
and therefore it is recommended that their doses should be reduced by 30-50% in PMs, if alternative
antidepressants cannot be selected. Fluoxetine itself is pharmacologically active, and it is converted
to a major active metabolite, R-norfluoxetine by CYP2D6. Therefore, CYP2D6 PMs have high
fluoxetine levels and low norfluoxetine levels, and their total sum may not vary to a clinically
significant degree between CYP2D6 genotypes.
The 5-hydroxytryptamine receptor antagonists ondansetron and tropisetron, that are used as
antiemetics, are metabolized to inactive metabolites to a significant degree by CYP2D6 (Bell, Caudle,
Whirl-Carrillo, Gordon, Hikino, Prows et al., 2017). Based on some pharmacokinetic data, the
metabolism and clearance of tropisetron is highly dependent on CYP2D6 phenotype, while the effect
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on ondansetron pharmacokinetics is only moderate. More importantly, there is clinical evidence
showing that CYP2D6 UMs are at risk of reduced antiemetic response to ondansetron and tropisetron.
Accordingly, the CPIC guideline gives a moderate recommendation to select an alternative antiemetic
approach in CYP2D6 UMs.
Tamoxifen is an antiestrogenic agent that is used in treatment of breast cancer. It is
bioactivated to 4-hydroxytamoxifen and endoxifen by CYP2D6 (Goetz, Sangkuhl, Guchelaar,
Schwab, Province, Whirl-Carrillo et al., 2018). Compared to NMs, CYP2D6 PMs exhibit lower
endoxifen concentrations and a higher risk of cancer recurrence when tamoxifen is used as an
adjuvant in early breast cancer. The CPIC guideline for tamoxifen therefore recommends the use of
alternative hormonal therapy for CYP2D6 poor metabolizers. For CYP2D6 IMs and NMs with an AS
of 1, the recommendation is to consider alternative hormonal therapy, or if aromatase inhibitor use is
contraindicated, to consider a higher but approved tamoxifen dose. For PMs, higher dose tamoxifen
(40 mg/day) can be considered if there are contraindications to aromatase inhibitor therapy.
7. CYP3A subfamily
The CYP3A subfamily consists of four genes, namely CYP3A4, CYP3A5, CYP3A7, CYP3A43 located
on chromosome 7q22.1. CYP3A4 and CYP3A5 are abundantly expressed in the adult liver (Zhang et
al., 2016). The expression of the other two isoforms is much lower, but CYP3A7 is abundantly
expressed in fetal liver, contributing to about 50% of the total microsomal CYP protein content.
CYP3A4 is important for the metabolism of about 50% of clinically used drugs including wide range
of drugs and drug classes: benzodiazepines, calcium channel blockers, cyclosporine, macrolide
antibiotics, opioids, several statins, and it also contributes to the metabolism of steroid hormones (S.
F. Zhou, 2008). CYP3A4 is inhibited by a wide range of xenobiotics, such as erythromycin, grapefruit
juice, ketoconazole, and HIV protease inhibitors. CYP3A4 is also highly inducible by PXR and CAR
ligands. CYP3A5 is highly similar to CYP3A4, resulting in highly overlapping substrate selectivity.
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7.1 CYP3A4
CYP3A4 activity is highly variable, but genetic variants in the CYP3A4 gene have explained only a
minor portion of this variability (Werk & Cascorbi, 2014). So far, the most relevant CYP3A4 variant
to explain CYP3A4 activity appears to be the intronic CYP3A4*22 (rs35599367 C>T) variant, which
occurs with a MAF of 5% in Europeans, and about 3% in admixed Americans, but is rare in many
other populations (Y. Zhou et al., 2017). In 2011 it was shown to be associated with reduced CYP3A4
mRNA  expression  in  liver  samples,  and  with  lower  statin  dose  requirement  for  lipid  control  (D.
Wang, Guo, Wrighton, Cooke, & Sadee, 2011). These findings have been subsequently replicated in
several studies (Werk & Cascorbi, 2014). On the other hand, another widely studied variant,
CYP3A4*1B, appears to have no or very limited functional impact on CYP3A4 (García-Martín,
Martínez, Pizarro, Garcia-Gamito, Gullsten, Raunio et al., 2002), in contrast to some initial reports
which may have been influenced by its linkage disequilibrium with CYP3A5*1. In addition to several
non-synonymous exonic variants, two total loss-of-function variants have been described
(CYP3A4*20 and *26), both initially discovered based on single individuals with abnormal
pharmacokinetics (Werk, Lefeldt, Bruckmueller, Hemmrich-Stanisak, Franke, Roos et al., 2014;
Westlind-Johnsson, Hermann, Huennemeyer, Hauns, Lahu, Nassr et al., 2006). The frequency of
these alleles is generally very low, but for example CYP3A4*20 is present in the Spanish population
with an allele frequency of 1.2% (Apellaniz-Ruiz, Inglada-Perez, Naranjo, Sanchez, Mancikova,
Curras-Freixes et al., 2015).
The association of CYP3A4*22 with reduced metabolic activity for several CYP3A4
substrates such as cyclosporine, erythromycin, sunitinib, tamoxifen, and quetiapine is well
established (Werk & Cascorbi, 2014). Few studies have reported effects on pharmacodynamic
endpoints for e.g., fluticasone in asthma and CYP3A4-metabolized statins in lipid control. However,
no genotype-based dosing guidelines have been published for CYP3A4.
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7.2 CYP3A5
CYP3A5 substrate selectivity overlaps with that of CYP3A4, and CYP3A5 contributes significantly
to the CYP3A metabolic activity in individuals who express fully functional CYP3A5, i.e., in carriers
of at least one CYP3A5*1 allele (Kuehl, Zhang, Lin, Lamba, Assem, Schuetz et al., 2001). The most
common and well-studied non-functional variant allele is the CYP3A5*3 (Lamba, Hebert, Schuetz,
Klein, & Altman, 2012). This allele is very common in admixed Americans, Europeans, East Asians,
and South Asians, constituting the major allele with a frequency of 80%, 94%, 71%, and 67%,
respectively (Y. Zhou et al., 2017). The allele frequency has been reported to correlate with the
distance from the equator (Thompson, Kuttab-Boulos, Witonsky, Yang, Roe, & Di Rienzo, 2004),
and it is considerably rarer in Africans (allele frequency 17%) than in other superpopulations. Other
nonfunctional alleles are generally rare, but CYP3A5*6 and *7 occur in African populations with
allele frequencies of 15% and 10% (Y. Zhou et al., 2017).
The strongest evidence for clinical implications of CYP3A5 variation is available for
tacrolimus, which is one of the most widely used immunosuppressive medications in solid organ
transplantation. Blood concentrations of tacrolimus have been associated with CYP3A5 genotype in
numerous studies, and CYP3A5 expressers have a higher tacrolimus clearance than non-expressers
(Birdwell, Decker, Barbarino, Peterson, Stein, Sadee et al., 2015). Therapeutic drug monitoring is
employed with tacrolimus therapy, and studies have shown that CYP3A5 genotyping is helpful for
achieving target trough whole blood concentrations when treatment is initiated. Less evidence is
available on its effect on clinical outcomes. Furthermore, in liver transplant patients, both the
genotype of the recipient and that of the donor liver can influence tacrolimus clearance, since
CYP3A5 is expressed in both the intestine and the liver. However, the evidence is inconclusive at the
moment regarding the relative significance of donor’s and recipient’s genotypes in liver transplants
where the genotype is different between the two.
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The evidence regarding CYP3A5 genotype and statins metabolized by CYP3A enzymes
is somewhat controversial, as some studies have shown poorer LDL-response to statin therapy in
CYP3A5 expressors than in non-expressors (Kivistö, Niemi, Schaeffeler, Pitkälä, Tilvis, Fromm et
al., 2004), whereas other studies have implicated reduced response in CYP3A5 non-expressors
(Willrich, Hirata, Genvigir, Arazi, Rebecchi, Rodrigues et al., 2008). Furthermore, there is limited
evidence that CYP3A5*3 is associated with statin-induced myopathy. In one study, atorvastatin-
associated myalgia cases with the CYP3A5*3/*3 genotype had higher creatine kinase levels than those
with the CYP3A5*1/*3 genotype  (Wilke,  Moore,  & Burmester,  2005).  In  addition,  an  association
with the CYP3A5 genotype and treatment-related toxicity has been reported for the anticancer agents
sunitinib and vincristine, which are both metabolized by CYP3A enzymes (Egbelakin, Ferguson,
MacGill, Lehmann, Topletz, Quinney et al., 2011; Garcia-Donas, Esteban, Leandro-Garcia,
Castellano, del Alba, Climent et al., 2011). However, due to limited evidence, no other genotype-
based dosing guidelines than those for tacrolimus have been published for CYP3A5 to date.
8. Conclusion
Due to substantial research efforts, there has been a tremendous progress in understanding the genetic
variability of drug-metabolizing CYP enzymes, their genotype-phenotype relationships, as well as
their clinical significance. During the last decade, important advances have included
- the discovery and characterization of the clinical relevance of certain fairly common
functionally relevant CYP alleles (particularly CYP2C19*17 and CYP3A4*22),
- recognition of the significance of CYP alleles common in individuals of non-European
ancestry (e.g., certain decreased function CYP2C9 alleles),
- understanding of the significance of rare loss-of-function CYP variants,
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- realization that in all populations, the proportion that possess an “actionable pharmacogene”
(i.e., a pharmacogenetic variant which is associated with actionable prescribing decision for a
specific drug) is very high,
- detailed characterization of the clinical usefulness of pharmacogenetic approaches related to
specific drugs (even prospective, randomized controlled clinical trials of pharmacogenetics
versus conventional approaches have been conducted with warfarin),
- and perhaps most importantly the systematic production of drug specific evidence-based
pharmacogenetic guidelines.
At the same time with increased understanding of the pharmacogenetics of CYP enzymes, there
has been a rapid movement from traditional genotyping towards an era of large-scale exome and
genome sequencing. This has already now increased the number of reported rare non-synonymous
CYP variants to thousands (Fujikura, Ingelman-Sundberg, & Lauschke, 2015). Such variants of
uncertain significance will pose a special challenge to pharmacogenetics, since they may have a very
large impact on drug pharmacokinetics when they are present as a diplotype together with a common
loss-of-function variant. Improvement of various computational approaches and large-scale
functional assays will be needed to make significant progress in understanding the significance of
such  a  multitude  of  rare  variants,  since  there  will  be  no  possibility  to  investigate  each  of  them
clinically.
Despite all the scientific advances, the incorporation of pharmacogenetic information to
clinical routine has been slow. So far, only few hospitals worldwide have adapted large-scale pre-
emptive genotyping in clinical use. The reasons for the slow progress include organizational, ethical,
legal and financial issues, in addition to medical issues. Sometimes, a main reason has been that
alternative drugs with a perceived or known more reliable clinical effect have become preferred, in
order to avoid pharmacogenetic complexities (Azmoon & Angiolillo, 2013).
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In the future, the discovery and characterization of pharmacogenes and their variants will
continue at a considerable rate, and work will be continued to compose and update pharmacogenetics
consensus guidelines. In addition, research efforts will be needed to characterize the clinical utility
and practicality of CYP genotyping in properly designed clinical trials. Moreover, incorporation of
the pharmacogenetics guidelines to health care routines will require development of computational
approaches, as well as electronic medical records and their interfaces, so that the use of
pharmacogenetics information to support medical decisions is smooth and effective; a key challenge
will be the provision of clear, unambiguous guidance to health care providers. At the same time, it
should be kept in mind that in addition to genetic variability, CYP phenotypes are altered by multiple
other individual factors, such as disease states and drug interactions.
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Table 1. Drug metabolizing CYP enzymes, their chromosomal location, clinical significance of their
genetic variability and examples of substrates. Substrates with an associated Clinical









CYP1A2 15q24.1 +/- Agomelatine, caffeine, clozapine, lidocaine,
melatonin, tacrine, theophylline, tizanidine
CYP2A6 19q13.2 + Cotinine, coumarin, letrozole, nicotine, tegafur
CYP2B6 19q13.2 + Bupropion, efavirenz, cyclophosphamide
CYP2C8 10q23.33 + Amodiaquine, cerivastatin, dasabuvir, imatinib,
loperamide, montelukast, pioglitazone, paclitaxel,
repaglinide, rosiglitazone
CYP2C9 10q23.33 ++ Acenocoumarol, diclofenac, fluvastatin, glimiepiride,
glipizide, ibuprofen, losartan, phenytoin, S-warfarin
CYP2C19 10q23.33 ++ Amitriptyline (and other tertiary amine tricyclic
antidepressants), clopidogrel, (es)citalopram,
omeprazole, pantoprazole, sertraline, voriconazole
CYP2D6 22q13.2 ++ Amitriptyline (and other tricyclic
antidepressants), aripiprazole, atomoxetine,
codeine, dextromethorphan, fluvoxamine,
metoprolol, mianserine, MDMA, ondansetron,
paroxetine, propafenone, risperidone, tamoxifen,
thioridazine, timolol, tropisetron, venlafaxine
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CYP2E1 10q26.3 +/- Ethanol, halothane, paracetamol
CYP2J2 1p32.1 +/- Amiodarone, arachidonic acid, astemizole,
cyclosporine
CYP3A4 7q22.1 +/- Alfentanil, alprazolam, atorvastatin, budesonide,
buspirone, cyclosporine, dexamethasone,
erythromycin, felodipine, gefitinib, lovastatin,
midazolam, nifedipine, quetiapine, saquinavir,
sildenafil, simvastatin, tacrolimus, testosterone,
triazolam, verapamil, vincristine
CYP3A5 7q22.1 ++ Saquinavir, tacrolimus, verapamil, substrates
overlap with CYP3A4
+/- Minor or no clinical significance
+ Moderate clinical significance
++ Major clinical significance
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Table 2. Assignment of likely phenotypes based on examples of common diplotypes. Phenotype
classification is based on consensus terms from the Clinical Pharmacogenetics Implementation
Consortium (CPIC) (Caudle et al., 2017).
Examples of diplotypes

































a xN represents the number of CYP2D6 gene copies.
b provisional classification.
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 Africans 1.8% 23% 75% - -
 Europeans 4.0% 32% 64% - -
 East Asians 0.1% 6.6% 93% - -
 South Asians 4.5% 33% 62% - -
 Americans 1.2% 20% 79% - -
CYPC19
 Africans 4.8% 24% 17% 16% 38%
 Europeans 2.5% 27% 39% 32% 0.0%
 East Asians 14% 47% 37% 1.7% 0.2%
 South Asians 12% 46% 23% 19% 0.0%
 Americans 2.3% 26% 47% 24% 0.0%
CYP2D6
 Africans 1.9% 13% 72% 4.5% 9.2%
 Europeans 6.1% 7.2% 75% 3.3% 8.5%
 East Asians 0.9% 8.7% 86% 1.2% 3.7%
 South Asians 1.3% 6.3% 89% 2.8% 0.4%
 Americans 3.7% 4.5% 81% 4.8% 5.8%
a For CYP2C19, rapid (CYP2C19*1/*17) and ultrarapid (CYP2C19*17/*17) metabolizers are
combined.
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b For CYP2C9, phenotypes are based on genotyping for defining SNVs of the decreased function
alleles CYP2C9*2, *3, *5, *6, *8, and *11, and all alleles that are negative for these SNVs are
defaulted to CYP2C9*1. For CYP2C19 and CYP2D6, alleles whose functional status is indeterminate
are included in the calculations.
Based on phenotype frequencies provided by PharmGKB and CPIC in Gene-specific Information
Tables (https://www.pharmgkb.org/page/cyp2c9RefMaterials,
https://www.pharmgkb.org/page/cyp2c19RefMaterials,
https://www.pharmgkb.org/page/cyp2d6RefMaterials; accessed 6 February 2018)
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